According to a new report by Polaris Market Research, the global pruritus therapeutics market was valued at USD 8.97 billion in 2025 and is projected to reach USD 12.61 billion by 2034, expanding at a CAGR of 5.50% over the forecast period. Growth is underpinned by the rising prevalence of dermatological and systemic conditions causing chronic itching, expanding biologics development, and accelerating adoption of personalized treatment approaches across key end-use industries.

What Is Driving Pruritus Therapeutics Market Growth?

Demand is climbing as the increasing prevalence of dermatological conditions converges with growing awareness of pruritus's impact on patient quality of life. Manufacturers and healthcare providers are prioritizing biologics and targeted immunomodulators, pushing pruritus therapeutics adoption across atopic dermatitis, urticaria, and allergic contact dermatitis management. Polaris analysts note that the aging global population and advances in drug delivery systems position the segment for steady growth through 2034, with atopic dermatitis emerging as the largest revenue contributor and biologic therapies posting notable incremental gains.

Key Trends Shaping the Pruritus Therapeutics Industry

Rise of Biologic Drugs and Immunomodulators

Development and adoption of biologic drugs and immunomodulators that specifically target the molecular mechanisms underlying pruritus is expanding the treatment arsenal beyond conventional corticosteroids and antihistamines.

Advanced Drug Delivery Systems

Integration of advanced drug delivery technologies is enhancing the efficacy and compliance of topical treatments, improving patient adherence and treatment outcomes across chronic pruritus conditions.

Growing Focus on Personalized Medicine

Increasing focus on hyper-personalized treatment approaches, tailored to individual patient conditions and therapy response, is reshaping how pruritus is managed across dermatological and systemic disease categories.

Market Segmentation: Breaking Down the Pruritus Therapeutics Market

Polaris segments the pruritus therapeutics market by disease type, product, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Disease Type

The atopic dermatitis segment dominated the market in 2024, given its high prevalence and chronic nature, which often includes severe and persistent itching as a primary symptom across both children and adult populations. Advancements in understanding the immunological and genetic underpinnings of atopic dermatitis continue to spur development of targeted biologics designed specifically to alleviate pruritus.

By Product

The corticosteroids segment held the dominant revenue share in 2024, given decades of established clinical use, proven efficacy in reducing inflammation and itching, and availability across multiple topical and systemic formulations. Their cost-effectiveness and rapid symptom relief continue to make them a mainstay of first-line pruritus management, even as newer biologic options expand.

Regional Outlook: Where Is Pruritus Therapeutics Growing Fastest?

North America dominated the market, contributing over 36% share of pruritus therapeutics revenue, supported by a high prevalence of dermatological conditions, advanced healthcare infrastructure, and extensive insurance coverage that facilitates access to both established and innovative therapies. Asia Pacific is anticipated to grow substantially, driven by rising prevalence of dermatological conditions, improving healthcare infrastructure, and increasing awareness of chronic pruritus's impact on quality of life in China, India, and Japan.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/global-pruritus-therapeutics-market 

Competitive Landscape: Leading Pruritus Therapeutics Companies

Key players profiled in the report include AbbVie Inc., Amgen Inc., Sanofi, and Novartis AG, who are focusing on expanding biologic and immunomodulator pipelines, strategic collaborations, and clinical development to strengthen market position across the atopic dermatitis and corticosteroids segments outlined above. Recent moves include Hoth Therapeutics' April 2025 positive interim Phase 2a results for HT-001, showing a 50% reduction in pruritus severity by Day 21, and Galderma's February 2024 FDA acceptance of its Biologics License Application for nemolizumab targeting prurigo nodularis and atopic dermatitis.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the pruritus therapeutics market, this report benchmarks market share, segment-level pricing, and forecast data — by disease type, product, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking biologic therapies as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Graphite Coating Market

Usage Based Insurance Market

Algae Oil Market

Pad-mounted Switchgear Market

Usage Based Insurance Market

Solar Panels Market

Zinc Oxide Market

Increasing Requirement for Clinically Qualified Resources to Boost Demand for Hospital Outsourcing

U.S. Desiccant Dehumidifier Market